Walter Yee, MD
Family Medicine · Elmhurst, NYNPI 1326076613
Payments from drug & device makers
Across 320 payments — averaging $106.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$5K
- AbbVie$5K
- Novo Nordisk$4K
- Boehringer Ingelheim$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Johnson & Johnson$2K
- plus $13K from 32 others
What the payments were for
- Consulting fees$1,2004%
- Travel & lodging$680%
- Food & beverage$32,82996%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 77 | $4,867 |
| AbbVie(2 entities) | 38 | $4,537 |
| Novo Nordisk | 32 | $3,870 |
| Boehringer Ingelheim | 28 | $3,487 |
| Teva Pharmaceuticals USA, Inc. | 20 | $2,439 |
| Johnson & Johnson | 16 | $1,621 |
| Biohaven Pharmaceuticals, Inc. | 3 | $1,393 |
| Amgen | 9 | $1,117 |
| E.r. Squibb & Sons, L.L.C. | 8 | $1,000 |
| Lilly USA, LLC | 9 | $969 |
| Esperion Therapeutics, Inc. | 7 | $874 |
| Grifols USA, LLC | 6 | $631 |
| Axsome Therapeutics, Inc. | 5 | $614 |
| GSK | 5 | $592 |
| Bayer | 8 | $570 |
| Sunovion Pharmaceuticals Inc. | 5 | $555 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $494 |
| Gilead | 4 | $472 |
| Otsuka America Pharmaceutical, Inc. | 4 | $471 |
| Abbott | 3 | $433 |
| Sanofi-aventis U.S. LLC | 3 | $337 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $250 |
| Avanir Pharmaceuticals, Inc. | 2 | $250 |
| Intra-sana Laboratories | 3 | $249 |
| Eisai Inc. | 2 | $249 |
| Seagen Inc. | 2 | $248 |
| Pfizer | 2 | $247 |
| Stryker | 1 | $162 |
| Ipsen Biopharmaceuticals, Inc | 1 | $150 |
| Amarin Pharma, Inc. | 3 | $137 |
| Luye Pharma (USA) Ltd. | 1 | $130 |
| Genentech USA, Inc. | 1 | $125 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $123 |
| Biogen | 1 | $100 |
| QOL Medical, LLC | 1 | $84 |
| Radius Health, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,116 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 112 | $163,466 |
| FarxigaDapagliflozin Propanediol | 87 | $114,028 |
| Xigduo XrDapaglifloz Propaned/Metformin | 78 | $99,950 |
| EliquisApixaban | 102 | $97,926 |
| JardianceEmpagliflozin | 73 | $90,357 |
| TrulicityDulaglutide | 38 | $61,716 |
| Bydureon BciseExenatide Microspheres | 32 | $54,231 |
| XareltoRivaroxaban | 31 | $42,461 |
| KerendiaFinerenone | 31 | $38,372 |
| MounjaroTirzepatide | 16 | $22,219 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $18,926 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,675 |
| LinzessLinaclotide | 17 | $15,664 |
| Metformin Hcl | 141 | $14,391 |
| ZenpepLipase/Protease/Amylase | 12 | $12,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,870 | $163,466112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $4,867 | $121,89598 claims |
| PfizerEliquis | $247 | $97,926102 claims |
| Boehringer IngelheimJardiance | $3,487 | $90,35773 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $969 | $83,93554 claims |
| Johnson & JohnsonXarelto | $1,621 | $42,46131 claims |
| BayerKerendia | $570 | $38,37231 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $592 | $22,33937 claims |
| AbbVieLinzess, Synthroid | $4,537 | $19,56073 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Elmhurst
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.